Primary uveal malignant melanoma

Dr Henry Knipe and Dr Praveen Jha et al.

Malignant uveal melanomas, also referred as choroidal melanomas, are the most common primary tumour of the adult eye 3

Malignant melanoma of the uvea is the most common primary intraocular malignancy and is predominantly seen in Caucasians 5. The incidence of these tumours increases with age, with only 2% of tumours found in patients younger than 20 years of age 6

Clinical presentation depends on the location. When the tumour is located on the iris, then it may be apparent to the patient or friends and family as a brown nodule. Choroidal or ciliary body tumours are only identified incidentally on fundoscopy or as a result of retinal detachment or advanced disease.

Uveal melanomas arise from the ciliary body or the choroid. Three histological types are recognised 5

  • mixed melanoma: containing both spindle B cell and epithelioid cells
  • epithelioid melanoma
  • necrotic melanoma

Ultrasound is an excellent modality for examining the globe and can visualise small plaque-like or discoid uveal melanoma, with a thickness of less than 3 mm, which are usually difficult to assess on CT or MRI. Features include 4

  • solid low to medium echotexture
  • internal vascularity
  • collar button shape
    • this is the classic shape but not always the case
    • represents the tumour having broken through Bruch's membrane
    • tumours may be irregular, lobulated or domed

Other features sometimes present include retinal detachment, posterior scleral bowing, choroidal excavation and vitreous or subretinal seeding. Additionally, larger tumours are often significantly sound attenuating 4.

CT is able to identify most uveal melanomas which appear as elevated, hyperdense sharply marginated lenticular or mushroom shaped lesions, which enhance with the administration of contrast.

MRI is the modality of choice for assessment of malignant uveal melanomas 5-6.

  • T1 or PD
    • uveal melanomas are seen as moderately high signal mass lesion (melanin and haemorrhage are responsible for the high signal)
    • associated exudative retinal detachment is moderately high signal
  • T2
    • moderately low signal mass lesion
    • associated exudative retinal detachment is moderately high signal
    • haemorrhagic subretinal fluid has a variable signal pattern
  • T1 C+ (Gd)
    • tumours enhance
    • fat suppression useful in detecting extraocular extension

Treatment for uveal malignant melanoma depends on tumour size and clinician's preference. Options include photocoagulation, transpupillary thermotherapy (TTT), brachytherapy, local excision, or enucleation 5-6.

Poor prognostic factors for systemic disease include 5:

  • older age: >60 years of age
  • larger tumours
  • anterior location within the globe
  • epithelioid cells (i.e. mixed or epithelioid histology)
  • extraocular extension, which usually occurs along the ciliary vessels and nerves, and less commonly along the optic nerve 9

Systemic metastases may be widespread (liver > lung > bone > kidney > brain) 6. They can metastasize late to the liver, with delays of 10 to 15 year from the presentation. 

Overall survival depends on tumour size, extraocular spread, and metastases. Even small (<10 mm diameter, <3 mm thickness) tumours still carry a 10-15% 5-year mortality 6.

Share article

Article information

rID: 8552
Section: Pathology
Synonyms or Alternate Spellings:
  • Malignant uveal melanomas
  • Malignant uveal melanoma
  • Choroidal melanoma
  • Choroidal melanomas

Support Radiopaedia and see fewer ads

Cases and figures

  • Drag
    Case 1: T1 C+ FS
    Drag here to reorder.
  • Drag
    Case 2: CT C+ : Orbital melanoma
    Drag here to reorder.
  • Drag
    Case 3
    Drag here to reorder.
  • Drag
    Fused PET- CT ima...
    Case 4: PET-CT
    Drag here to reorder.
  • Drag
    Axial T1 fat sat ...
    Case 5
    Drag here to reorder.
  • Updating… Please wait.
    Loadinganimation

    Alert accept

    Error Unable to process the form. Check for errors and try again.

    Alert accept Thank you for updating your details.